Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Cash & Equivalents (2017 - 2025)

Dr Reddys Laboratories (RDY) has 8 years of Cash & Equivalents data on record, last reported at $85.6 million in Q1 2024.

  • For Q1 2024, Cash & Equivalents rose 21.73% year-over-year to $85.6 million; the TTM value through Mar 2024 reached $85.6 million, up 21.73%, while the annual FY2025 figure was $172.0 million, 100.34% up from the prior year.
  • Cash & Equivalents reached $85.6 million in Q1 2024 per RDY's latest filing, up from $70.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $203.4 million in Q1 2021 and bottomed at $28.3 million in Q1 2020.
  • Average Cash & Equivalents over 5 years is $117.0 million, with a median of $85.6 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 617.66% in 2021, then plummeted 64.41% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $28.3 million in 2020, then surged by 617.66% to $203.4 million in 2021, then decreased by 2.88% to $197.5 million in 2022, then tumbled by 64.41% to $70.3 million in 2023, then rose by 21.73% to $85.6 million in 2024.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $85.6 million in Q1 2024, $70.3 million in Q1 2023, and $197.5 million in Q1 2022.